Skip to search formSkip to main contentSkip to account menu

moguisteine

Known as: 2-(2-methoxyphenoxy)methyl-3-ethoxycarbonylacetyl-1,3-thiazolidine, 3-Thiazolidinepropanoic acid, 2-((2-methoxyphenoxy)methyl)-beta-oxo-, ethyl ester, (+-)-, ethyl 2-((2-methoxyphenoxy)methyl)-beta-oxothiazolidine-3-propanoate 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Cough is one of the most common symptoms for which patients seek medical attention from primary care physicians and… 
Review
2007
Review
2007
Chronic cough is a common symptom but only a fraction of patients seek medical attention. Addressing the causes of chronic cough… 
Review
2006
Review
2006
BACKGROUND Cough-suppressant therapy, previously termed nonspecific antitussive therapy, incorporates the use of pharmacologic… 
Review
2001
Review
2001
BACKGROUND Acute cough due to upper respiratory tract infection (URTI) is a common symptom. Many health practitioners recommend… 
Review
2001
Review
2001
BACKGROUND Acute cough due to upper respiratory tract infection (URTI) is a common symptom. Many health practitioners recommend… 
1997
1997
With anaesthetized guinea pigs, the actions of moguisteine were tested on the cough reflex, the resting discharge of lung rapidly… 
1995
1995
We conducted a multicentre, double-blind, parallel group study to compare the clinical efficacy of a new antitussive drug… 
1994
1994
SummaryCough is a protective mechanism and an important symptom of many respiratory diseases. When coughing is only an annoying… 
1994
1994
1 The antitussive effects of moguisteine have been compared with codeine in several experimental models of cough in guinea‐pigs… 
1993
1993
This completely randomised, double-blind, placebo-controlled, multicentre trial was carried out to evaluate the antitussive…